Actavis has received two separate approvals from the US Food & drug administration to market Bupropion Hydrochloride extended-release tablets. 

Bupropion Hydrochloride extended-release tablets, available in 150mg strength, are the generic equivalent of Wellbutrin and are indicated for the treatment of major depressive disorder. Annual sales of brand and generic Wellbutrin were US $498 million for the 12 months ending December 2007 according to IMS Health data.

Bupropion Hydrochloride extended-release tablets, available in 150mg strength, are the generic equivalent of Zyban and are indicated as an aid to smoking cessation treatment.